LAVIOLETTE PAUL A 4/A

What Happened

• Paul A. Laviolette, CEO of Pulse Biosciences (PLSE), acquired 15,000 shares on May 11, 2026, in an open-market/ATM purchase at $19.69 per share, for a total reported cost of $295,350. This transaction is a purchase (Form 4 code P), which is a direct buy of company stock.

Key Details

• Transaction date and price: 2026-05-11 — 15,000 shares at $19.69 each (total $295,350).
• Transaction type: Open-market purchase through the company’s at-the-market (ATM) equity offering program (Form 4 code P).
• Filing status: This submission is an amended Form 4. The filing does not indicate a late-reporting code in the data provided.
• Shares owned after transaction: Not specified in the information provided in this summary filing.
• Notable footnotes from the filing:
  • F1/F2: Shares were acquired through the company’s ATM equity offering program (Equity Distribution Agreement with TD Securities (USA) LLC) and were purchased at the prevailing market bid price or better during an open trading window and in compliance with insider policy and securities laws.
  • F3: The filing also references shares purchased through the company’s Employee Stock Purchase Plan (ESPP) in March 2026.

Context

• ATM purchases are executed into the market over time through a sales agent; they are open-market buys rather than a private negotiated issuance to the insider. Purchases by insiders can be interpreted by some investors as a positive/affirmative signal, but they do not, by themselves, explain motivation or future company performance.
• This is an amendment to the original Form 4 filing; amendments commonly correct or clarify previously reported details.